Charles River Laboratories International (CRL) to Release Earnings on Thursday

Charles River Laboratories International (NYSE:CRL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $2.05 per share for the quarter. Charles River Laboratories International has set its FY24 guidance at $10.90-11.40 EPS and its FY 2024 guidance at 10.900-11.400 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. During the same period in the prior year, the business posted $2.98 earnings per share. The company’s revenue for the quarter was down 7.9% on a year-over-year basis. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Price Performance

CRL opened at $236.30 on Wednesday. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The business has a fifty day moving average of $251.61 and a 200 day moving average of $225.17. Charles River Laboratories International has a 52-week low of $161.65 and a 52-week high of $275.00. The stock has a market cap of $12.17 billion, a P/E ratio of 25.66, a PEG ratio of 1.83 and a beta of 1.44.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRL. Citigroup boosted their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. UBS Group upped their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Evercore ISI increased their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. lifted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.23.

Insider Transactions at Charles River Laboratories International

In related news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. In the last three months, insiders sold 14,932 shares of company stock valued at $3,693,663. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).